Judge upholds Lilly’s Evista patent

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.

Evista is an osteoporosis drug that generated global sales of $1 billion last year, including $700
million in the United States.

U.S. District Court Judge Sarah Evans Barker ruled that Lilly’s method-of-use
patents for Evista are valid through 2014, rejecting all the claims of Israel-based Teva Pharmaceuticals Industries Ltd.

However, Barker said Lilly’s patents on Evista’s particle size are invalid. Lilly said it is considering
whether to appeal that part of the ruling.

Teva has sought to market a cheaper generic version of Evista, also
known as raloxifene.
 

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In